---
title: Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
nct_id: NCT04124926
overall_status: COMPLETED
phase: PHASE3
sponsor: Phathom Pharmaceuticals, Inc.
study_type: INTERVENTIONAL
primary_condition: Erosive Esophagitis
countries: United States, Bulgaria, Czechia, Hungary, Poland, United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04124926.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04124926"
ct_last_update_post_date: 2022-07-29
last_seen_at: "2026-05-12T06:45:41.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

**Official Title:** A Phase 3, Randomized, Double-Blind, Two Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients With Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients With Healed Erosive Esophagitis

**NCT ID:** [NCT04124926](https://clinicaltrials.gov/study/NCT04124926)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 1027
- **Lead Sponsor:** Phathom Pharmaceuticals, Inc.
- **Conditions:** Erosive Esophagitis
- **Start Date:** 2019-10-28
- **Completion Date:** 2021-08-24
- **CT.gov Last Update:** 2022-07-29

## Brief Summary

To evaluate the efficacy and safety of vonoprazan compared to lansoprazole in participants with erosive esophagitis.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. The participant is ≥18 years of age at the time of informed consent signing.
2. In the opinion of the investigator or subinvestigators, the participant is capable of understanding and complying with protocol requirements.
3. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. The participant is informed of the full nature and purpose of the study, including possible risks and side-effects. The participant has the ability to cooperate with the investigator. Ample time and opportunity should be given to read and understand verbal and/or written instructions.
4. The participant is found to have endoscopically confirmed EE of LA Classification Grades A to D during the Screening Period (Visit 1) as assessed by a central adjudicator. The target number of participants with LA classification Grade C or D will be approximately 30% of the total number of participants (300 total). Enrollment of EE participants with Grade A or B will end when the number of participants with Grade A or B EE is approximately 700 or 70% of the total planned number of participants. Given the invasive nature of an endoscopy, any endoscopic confirmation performed in a routine clinical setting before signing the informed consent will be acceptable to use for the purpose of fulfilling the screening requirement if all of the following apply: (1) appropriate endoscopy pictures were taken; (2) appropriate gastric biopsy samples were taken; (3) the endoscopy pictures can be sent to the central adjudicator via the adjudication systems; and (4) all screening procedures (including the completion of adjudication) AND randomization can be completed within a 7-day period after the date of the endoscopy.
5. A female participant of childbearing potential who is or may be sexually active with a nonsterilized male partner agrees to routinely use adequate contraception from the signing of informed consent until 4 weeks after the last dose of study drug.

Exclusion Criteria:

1. The participant's endoscopic examination for entering this study fails to confirm EE within 7 days (no later than 10 days on rare occasion with sponsor approval) prior to randomization.
2. The participant is determined to be positive for Helicobacter pylori (HP) or has had an HP infection within 45 days of randomization.
3. The participant has endoscopic Barrett's esophagus (\>1 cm of columnar-lined esophagus) and/or definite dysplastic changes in the esophagus.
4. The participant has any other condition affecting the esophagus, including eosinophilic esophagitis; esophageal varices; viral or fungal infection; esophageal stricture; a history of radiation therapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy to the esophagus; or any history of caustic or physiochemical trauma (including sclerotherapy or esophageal variceal band ligation). However, participants diagnosed with Schatzki's ring (mucosal tissue ring around lower esophageal sphincter) are eligible to participate.
5. The participant has scleroderma (systemic sclerosis).
6. The participant has a history of surgery or endoscopic treatment affecting gastroesophageal reflux, including fundoplication and dilation for esophageal stricture (except Schatzki's ring) or a history of gastric or duodenal surgery (except endoscopic removal of benign polyps).
7. The participant has an active gastric or duodenal ulcer at the start of the Screening Period. Additionally, participants with gastric or duodenal erosions are permitted to participate.
8. The participant has received any investigational compound (including those in post marketing studies) within 30 days prior to the start of the Screening Period. A participant who has been screen failed from another clinical study and who has not been dosed may be considered for enrollment in this study.
9. The participant is a study site employee, an immediate family member, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or who may have consented under duress.
10. The participant has cutaneous lupus erythematosus or systemic lupus erythematosus.
11. The participant has had clinically significant upper or lower gastrointestinal bleeding within 4 weeks prior to randomization.
12. The participant has Zollinger-Ellison syndrome or other gastric acid hypersecretory conditions.
13. The participant has a history of hypersensitivity or allergies to vonoprazan (including the formulation excipients: D-mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, titanium oxide, or red or yellow ferric oxide), PPIs, or any excipients used in the 13C-urea breath test: mannitol, citric acid, or aspartame. Skin testing may be performed according to local standard practice to confirm hypersensitivity.
14. The participant has a history of alcohol abuse, illegal drug use, or drug addiction within the 12 months prior to screening, or regularly consumes \>21 units of alcohol (1 unit = 12 oz/300 mL beer, 1.5 oz/25 mL hard liquor/spirits, or 5 oz/100 mL wine) per week based on self-report. Participants must have a negative urine drug screen at screening.
15. The participant is taking any excluded medications or treatments.
16. If female, the participant is pregnant, lactating, or intending to become pregnant before, during, or within 4 weeks after participating in this study; or intending to donate ova during such time period.
17. The participant has a history or clinical manifestations of significant central nervous system, cardiovascular, pulmonary, hepatic, renal, metabolic, other gastrointestinal, urological, endocrine, or hematological disease that, in the opinion of the investigator, would confound the study results or compromise participant safety.
18. The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Visit.
19. The participant has a history of malignancy (including MALToma) or has been treated for malignancy within 5 years prior to the start of the Screening Period (Visit 1). (The participant may be included in the study if he/she has cured cutaneous basal cell carcinoma or cervical carcinoma in situ).
20. The participant has acquired immunodeficiency syndrome or human immunodeficiency virus infection, or tests positive for the hepatitis B surface antigen, hepatitis C virus (HCV) antibody, or HCV RNA. However, participants who test positive for HCV antibody but negative for HCV RNA are permitted to participate.
21. The participant has any of the following abnormal laboratory test values at the start of the Screening Period:

    1. Creatinine levels: \>2 mg/dL (\>177 μmol/L)
    2. Alanine aminotransferase or aspartate aminotransferase \>2 × the upper limit of normal (ULN) or total bilirubin \>2 × ULN.
```

## Arms

- **Healing Phase: Vonoprazan 20 mg** (EXPERIMENTAL) — Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 8 weeks.
- **Healing Phase: Lansoprazole 30 mg** (ACTIVE_COMPARATOR) — Participants will receive oral lansoprazole 30 mg once per day (QD) for a maximum of 8 weeks.
- **Maintenance Phase: Vonoprazan 10 mg** (EXPERIMENTAL) — Participants will receive oral vonoprazan 10 mg once per day (QD) for a maximum of 24 weeks.
- **Maintenance Phase: Vonoprazan 20 mg** (EXPERIMENTAL) — Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 24 weeks.
- **Maintenance Phase: Lansoprazole 15 mg** (ACTIVE_COMPARATOR) — Participants will receive oral lansoprazole 15 mg once per day (QD) for a maximum of 24 weeks.

## Interventions

- **Vonoprazan** (DRUG) — Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
- **Lansoprazole** (DRUG) — Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.

## Primary Outcomes

- **Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8** _(time frame: Week 8)_ — A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
- **Maintenance Phase: Percentage of Participants Who Maintained Complete Healing of EE at Week 24** _(time frame: Week 24)_ — A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.

## Secondary Outcomes

- **Healing Phase: Percentage of 24-hour Heartburn-free Days** _(time frame: Day 1 to Week 8)_
- **Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE at Week 2** _(time frame: Week 2)_
- **Healing Phase: Percentage of Participants With Onset of Sustained Resolution of Heartburn by Day 3** _(time frame: Day 1 to maximum of Day 10 (inclusive of 7 day heartburn assessment))_
- **Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE by Week 8** _(time frame: Week 8)_
- **Healing Phase: Percentage of Participants Who Had Complete Healing of EE at Week 2** _(time frame: Week 2)_
- **Maintenance Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Maintained Complete Healing of EE at Week 24** _(time frame: Week 24)_
- **Maintenance Phase: Percentage of 24-hour Heartburn-free Days** _(time frame: Day 1 to Week 24)_

## Locations (157)

- Pinnacle Research Group, Anniston, Alabama, United States
- North Alabama Research Center LLC, Athens, Alabama, United States
- Synexus Clinical Research US, Inc., Birmingham, Alabama, United States
- Medical Affiliated Research Center Inc, Huntsville, Alabama, United States
- Synexus Clinical Research US, Inc. - East Valley Family Physicians, PLC, Chandler, Arizona, United States
- Synexus Clinical Research US, Inc. - Central Arizona Medical Associates, PC, Mesa, Arizona, United States
- Synexus Clinical Research US, Inc. - Desert Clinical Research, LLC, Mesa, Arizona, United States
- Elite Clinical Studies - Phoenix - BTC - PPDS, Phoenix, Arizona, United States
- Hope Research Institute LLC, Phoenix, Arizona, United States
- Del Sol Research Management - BTC - PPDS, Tucson, Arizona, United States
- Preferred Research Partners - ClinEdge - PPDS, Little Rock, Arkansas, United States
- Applied Research Center of Little Rock, Little Rock, Arkansas, United States
- Arkansas Gastroenterology, North Little Rock, Arkansas, United States
- Atria Clinical Research - BTC - PPDS, North Little Rock, Arkansas, United States
- Anaheim Clinical Trials LLC, Anaheim, California, United States
- GW Research, Inc. - ClinEdge - PPDS, Chula Vista, California, United States
- eStudySite - Chula Vista - PPDS, Chula Vista, California, United States
- Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States
- HB Clinical Trials, Inc., Fountain Valley, California, United States
- OM Research LLC, Lancaster, California, United States
- Torrance Clinical Research Institute, Lomita, California, United States
- LA County + USC Medical Center, Los Angeles, California, United States
- Southern California Research Institute Medical Group, Inc., Los Angeles, California, United States
- Facey Medical Foundation, Mission Hills, California, United States
- Palmtree Clinical Research, Palm Springs, California, United States
- Precision Research Institute, San Diego, California, United States
- Medical Associates Research Group, Inc., San Diego, California, United States
- Paragon Rx Clinical, Inc., Santa Ana, California, United States
- Synexus Clinical Research US, Inc. - Colorado Springs Family Practice, Colorado Springs, Colorado, United States
- Western States Clinical Research, Inc., Wheat Ridge, Colorado, United States
- Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States
- Connecticut Clinical Research Foundation, Bristol, Connecticut, United States
- Riverside Clinical Research, Edgewater, Florida, United States
- Research Centers of America - ERG, Hollywood, Florida, United States
- Nature Coast Clinical Research, Inverness, Florida, United States
- ENCORE Borland-Groover Clinical Research - ERN - PPDS, Jacksonville, Florida, United States
- Columbus Clinical Services LLC, Miami, Florida, United States
- Jesscan Medical Research, Miami, Florida, United States
- Nuren Medical and Research Center, Miami, Florida, United States
- Premier Research Associate, Inc., Miami, Florida, United States
- Gutierrez Medical Center, Orlando, Florida, United States
- Advanced Gastroenterology Associates, LLC, Palm Harbor, Florida, United States
- Innovation Medical Research Center, Palmetto Bay, Florida, United States
- Synexus Clinical Research US, Inc. - St. Petersburg, Pinellas Park, Florida, United States
- Precision Clinical Research, LLC, Sunrise, Florida, United States
- Guardian Angel Research Center, Tampa, Florida, United States
- Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
- Nexgen Research Center, Atlanta, Georgia, United States
- Gastroenterology Associates of Central Georgia, LLC, Macon, Georgia, United States
- In-Quest Medical Research, LLC, Peachtree Corners, Georgia, United States
- Illinois Gastroenterology Group, Gurnee, Illinois, United States
- Summit Digestive & Liver Disease Specialists State Street Clinic, Oakbrook Terrace, Illinois, United States
- MediSphere Medical Research Center, LLC, Evansville, Indiana, United States
- Gastroenterology Health Partners, PLLC, New Albany, Indiana, United States
- Iowa Digestive Disease Center, Clive, Iowa, United States
- Clinical Trials Management LLC, Covington, Louisiana, United States
- CroNOLA, LLC., Houma, Louisiana, United States
- Clinical Trials Management LLC, Metairie, Louisiana, United States
- Louisiana Research Center, LLC, Shreveport, Louisiana, United States
- Meridian Clinical Research, Rockville, Maryland, United States
- Clinical Associates Research, Towson, Maryland, United States
- Oakland Medical Research Center, Troy, Michigan, United States
- Gastroenterology Associates of Western Michigan, PLC, Wyoming, Michigan, United States
- The Alliance for Multispecialty Research, LLC, Kansas City, Missouri, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Heartland Clinical Research, Inc, Omaha, Nebraska, United States
- Synexus Clinical Research US, Inc. Site 1, Henderson, Nevada, United States
- Synexus Clinical Research US, Inc. Site 2, Henderson, Nevada, United States
- Sierra Clinical Research - ClinEdge - PPDS, Las Vegas, Nevada, United States
- Site 2, Las Vegas, Nevada, United States
- Las Vegas - Site 1, Las Vegas, Nevada, United States
- Advanced Research Institute, Reno, Nevada, United States
- Drug Trials America - ClinEdge, Hartsdale, New York, United States
- Southtowns Gastroenterology, PLLC, Orchard Park, New York, United States
- Carolinas Research Center, Charlotte, North Carolina, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Medication Management LLC, Greensboro, North Carolina, United States
- Carolina Research, Greenville, North Carolina, United States
- Peters Medical Research, LLC - ClinEdge - PPDS, High Point, North Carolina, United States
- Carolina's GI Research, LLC, Raleigh, North Carolina, United States
- Dayton Gastroenterology, Inc, Dayton, Ohio, United States
- Prestige Clinical Research, Franklin, Ohio, United States
- Central Sooner Research, Norman, Oklahoma, United States
- Synexus Clinical Research US, Inc., Anderson, South Carolina, United States
- Clinical Trials of South Carolina, Charleston, South Carolina, United States
- Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States
- Rapid City Medical Center LLP, Rapid City, South Dakota, United States
- Multi Specialty Clinical Research, Johnson City, Tennessee, United States
- Clinical Research Associates Inc, Nashville, Tennessee, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Inquest Clinical Research, Baytown, Texas, United States
- Synexus Clinical Research US, Inc. - Dallas, Dallas, Texas, United States
- Texas Tech University Health Sciences Center El Paso, El Paso, Texas, United States
- Precision Research Institute, LLC, Houston, Texas, United States
- Biopharma Informatic, LLC, Houston, Texas, United States
- Rio Grande Gastroenterology, McAllen, Texas, United States
- Digestive System Healthcare, Pasadena, Texas, United States
- Pearland Physicians, Pearland, Texas, United States
- Synexus Clinical Research US, Inc., Plano, Texas, United States
- Quality Research Inc, San Antonio, Texas, United States
- Gastroenterology Research of San Antonio (GERSA), San Antonio, Texas, United States
- Southern Star Research Institute, LLC, San Antonio, Texas, United States
- Synexus Clinical Research US, Inc., Layton, Utah, United States
- Advanced Research Institute, Ogden, Utah, United States
- New River Valley Research Institute, Christiansburg, Virginia, United States
- Verity Research, Inc., Fairfax, Virginia, United States
- Blue Ridge Medical Research, Lynchburg, Virginia, United States
- Washington Gastroenterology, Bellevue, Washington, United States
- Harborview Medical Center, University of Washington Medical Center, Seattle, Washington, United States
- Fourth Multiprofile Hospital for Active Treatment, Sofia, Sofia-Grad, Bulgaria
- Multiprofile Hospital for Active Treatment Puls AD - PPDS, Blagoevgrad, Bulgaria
- University Multiprofile Hospital for Active Treatment, Pleven, Bulgaria
- Second Multiprofile Hospital for Active Treatment Sofia, Sofia, Bulgaria
- Medical Center Excelsior OOD - PPDS, Sofia, Bulgaria
- Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria
- Synexus - Medical Center Synexus Sofia EOOD, Sofia, Bulgaria
- Synexus - Medical Centre Synexus Sofia EOOD, Stara Zagora, Bulgaria
- Nemocnice Pardubickeho kraje, a.s. Orlickoustecka nemocnice, Interni oddeleni, Cs., Ústí nad Orlicí, Pardubice, Czechia
- MEDIC KRAL s.r.o., Prague, Prague, Czechia
- PreventaMed s.r.o., Olomouc, Czechia
- Synexus Czech s.r.o., Prague, Czechia
- Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z. Oddeleni gastroenterolgie, Ústí nad Labem, Czechia
- Debreceni Egyetem Klinikai Kozpont Nagyerdei Krt. 98, Belgyogyaszati Klinika, Debrecen, Hajdú-Bihar, Hungary
- Synexus Affiliate BKS Research Kft. Hatvan, Hatvan, Heves County, Hungary
- Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary
- Synexus (DRS) - Synexus Magyarország Kft. Budapest, Budapest, Hungary
- Synexus Affiliate - Synexus Magyarorszag Kft. Debrecen, Debrecen, Hungary
- Synexus (DRS) - Synexus Magyarorszag Kft. Gyula, Gyula, Hungary
- Synexus (DRS) - Synexus Magyarország Kft. Zalaegerszeg, Zalaegerszeg, Hungary
- Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy Centrum Endoskopii Zabiegowej - Poradnia Chorob Jelitowych, Bydgoszcz, Poland
- Gabinet Lekarski-Janusz Rudzinski ul. Powstancow Warszawy 5, Bydgoszcz, Poland
- Synexus - Czestochowa, Częstochowa, Poland
- Synexus - Gdansk, Gdansk, Poland
- Synexus - Gdynia, Gdynia, Poland
- Synexus - Katowice, Katowice, Poland
- Synexus Affiliate - Krakowskie Centrum Medyczne, Krakow, Poland
- Centrum Opieki Zdrowotnej Orkan-Med Stec-Michalska Sp. J., Ksawerów, Poland
- Synexus - Lodz, Lodz, Poland
- Santa Familia Centrum Badań Profilaktyki i Leczenia, Lodz, Poland
- GASTRO MED Zaklad Opieki Zdrowotnej, Lublin, Poland
- Synexus - Poznan, Poznan, Poland
- Korczowski Bartosz, Gabinet Lekarski, Rzeszów, Poland
- Twoja Przychodnia - Szczecińskie Centrum Medyczne, Szczecin, Poland
- Gastromed Specjalistyczne Centrum Gastrologii i Endoskopii, Torun, Poland
- REUMATIKA - Centrum Reumatologii NZOZ, Warsaw, Poland
- Synexus - Warszawa, Warsaw, Poland
- Synexus - Wroclaw, Wroclaw, Poland
- Melita Medical, Wroclaw, Poland
- Synexus Thames Valley Clinical Research Centre, Reading, Berkshire, United Kingdom
- Synexus - Midlands Clinical Research Centre, Edgbaston, West Midlands, United Kingdom
- Synexus - Wales Clinical Research Centre, Cardiff, United Kingdom
- Synexus - Lancashire Clinical Research Centre, Chorley, United Kingdom
- CPS Research, Glasgow, United Kingdom
- Synexus - Hexham Clinical Research Centre, Hexham, United Kingdom
- Synexus - Merseyside Clinical Research Centre, Liverpool, United Kingdom
- Synexus - Manchester Clinical Research Centre, Manchester, United Kingdom
- Synexus - North Tees Clinical Research Centre, Stockton-on-Tees, United Kingdom

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.pinnacle research group|anniston|alabama|united states` — added _(2026-05-12)_
- `locations.north alabama research center llc|athens|alabama|united states` — added _(2026-05-12)_
- `locations.synexus clinical research us, inc.|birmingham|alabama|united states` — added _(2026-05-12)_
- `locations.medical affiliated research center inc|huntsville|alabama|united states` — added _(2026-05-12)_
- `locations.synexus clinical research us, inc. - east valley family physicians, plc|chandler|arizona|united states` — added _(2026-05-12)_
- `locations.synexus clinical research us, inc. - central arizona medical associates, pc|mesa|arizona|united states` — added _(2026-05-12)_
- `locations.synexus clinical research us, inc. - desert clinical research, llc|mesa|arizona|united states` — added _(2026-05-12)_
- `locations.elite clinical studies - phoenix - btc - ppds|phoenix|arizona|united states` — added _(2026-05-12)_
- `locations.hope research institute llc|phoenix|arizona|united states` — added _(2026-05-12)_
- `locations.del sol research management - btc - ppds|tucson|arizona|united states` — added _(2026-05-12)_
- `locations.preferred research partners - clinedge - ppds|little rock|arkansas|united states` — added _(2026-05-12)_
- `locations.applied research center of little rock|little rock|arkansas|united states` — added _(2026-05-12)_
- `locations.arkansas gastroenterology|north little rock|arkansas|united states` — added _(2026-05-12)_
- `locations.atria clinical research - btc - ppds|north little rock|arkansas|united states` — added _(2026-05-12)_
- `locations.anaheim clinical trials llc|anaheim|california|united states` — added _(2026-05-12)_
- `locations.gw research, inc. - clinedge - ppds|chula vista|california|united states` — added _(2026-05-12)_
- `locations.estudysite - chula vista - ppds|chula vista|california|united states` — added _(2026-05-12)_
- `locations.kindred medical institute for clinical trials, llc|corona|california|united states` — added _(2026-05-12)_
- `locations.hb clinical trials, inc.|fountain valley|california|united states` — added _(2026-05-12)_
- `locations.om research llc|lancaster|california|united states` — added _(2026-05-12)_
- `locations.torrance clinical research institute|lomita|california|united states` — added _(2026-05-12)_
- `locations.la county + usc medical center|los angeles|california|united states` — added _(2026-05-12)_
- `locations.southern california research institute medical group, inc.|los angeles|california|united states` — added _(2026-05-12)_
- `locations.facey medical foundation|mission hills|california|united states` — added _(2026-05-12)_
- `locations.palmtree clinical research|palm springs|california|united states` — added _(2026-05-12)_
- `locations.precision research institute|san diego|california|united states` — added _(2026-05-12)_
- `locations.medical associates research group, inc.|san diego|california|united states` — added _(2026-05-12)_
- `locations.paragon rx clinical, inc.|santa ana|california|united states` — added _(2026-05-12)_
- `locations.synexus clinical research us, inc. - colorado springs family practice|colorado springs|colorado|united states` — added _(2026-05-12)_
- `locations.western states clinical research, inc.|wheat ridge|colorado|united states` — added _(2026-05-12)_
- `locations.gastroenterology associates of fairfield county|bridgeport|connecticut|united states` — added _(2026-05-12)_
- `locations.connecticut clinical research foundation|bristol|connecticut|united states` — added _(2026-05-12)_
- `locations.riverside clinical research|edgewater|florida|united states` — added _(2026-05-12)_
- `locations.research centers of america - erg|hollywood|florida|united states` — added _(2026-05-12)_
- `locations.nature coast clinical research|inverness|florida|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04124926.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04124926*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*